The current study and past reports of ATE-CXL for keratoconus
| Author | Year | Design | N* | F/U | Age | UV-A irradiation | Results |
| The current study | – | PCS | 90 | 36M | 14–50 | 30 mW/cm2 3 min continuous | Kmax, AvgK, Ks, UCVA, BCVA stable The speed of progression (Kmax, AvgK, Ks) improved |
| Zhang36 | 2020 | RCS | 42 | 48M | 18–35 | 45 mW/cm2 5 min 20 s pulse | Kmax, AvgK, Ks, Kf, astigmatism keratometry, CCT, TCT, posterior elevation stable |
| Tian23 | 2020 | PCS | 53 | 36M | 10–17 | 45 mW/cm2 5 min 20 s pulse | BCVA improved Kmax, corneal pachymetry, epithelial thickness stable posterior elevation increased |
| Huang37 | 2018 | PCS | 25 | 24M | N/A (25.4±6.0) | 45 mW/cm2 5 min 20 s pulse | Corneal astigmatism, K1, K2, AvgK, Kmax, CCT, TCT, anterior corneal elevation, posterior corneal elevation stable |
| Kir38 | 2017 | PCS | 48 | 24M | 18–33 | 45 mW/cm2 5 min 20 s pulse | AvgK, CCT, TCT, UCVA, BCVA stable |
| Artola39 | 2017 | PCS | 19 | 12M | 26–69 | 45 mW/cm2 5 min 20 s pulse | BCVA improved Refractive, corneal topographic and pachymetric parameters stable |
| Aixinjuelo30 | 2017 | PCS | 30 | 12M | 16–38 | 30 mW/cm2 3 min continuous | Kmax, AvgK, TCT, BCVA improved |
| Zhang40 | 2016 | PCS | 28 | 12M | 10–34 | 45 mW/cm2 5 min 20 s pulse | Kmax, TCT, BCVA stable UCVA improved |
| Shen41 | 2016 | RCS | 17 | 12M | 18–35 | 45 mW/cm2 5 min 20 s pulse | K1, K2, mean K, CCT, TCT stable significant improve in BCVA |
*Number of eyes CXL performed.
ATE-CXL, accelerated transepithelial corneal cross-linking; BCVA, best-corrected visual acuity; CCT, thinnest corneal thickness; F/U, follow-up periods; M, months; PCS, prospective case series; RCS, retrospective case series; RCT, randomised clinical trial; TCT, thinnest corneal thickness; TCT, thinnest corneal thickness; UCVA, uncorrected visual acuity; UV-A, ultraviolet A.